BioSpace News Archive

Life Sciences Investor Forum today announced that the presentations from the December 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive discussions focused on the life sciences industry. The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “vi

DW Healthcare Partners V, L.P. (“Purchaser”), announced today that it has commenced a cash tender offer for all of the outstanding ordinary shares of Parnell Pharmaceuticals Holdings Ltd (OTC Pink Open Market: PARNF) (“Parnell”) at a price of U.S. $0.40 per share, net to the seller in cash without interest and less applicable wi

Rx-360 is pleased to announce their 2021 Board of Directors. The Board is positioned to continue driving the Rx-360 mission of pharmaceutical supply chain security and patient safety. This announcement follows the successful growth of the organization in 2020 that brought an expansion of the Consortium Audit Program, and internati

Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, and 3E Bioventures Capital, a healthcare focused fund dedicated to investing in innovative therapeutics and frontier biomedical technologies, today announced the formation of the joint venture company Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. (BC Regenacy).

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today announced the appointments of Erin Whitney to Head of Global Clinical Operations, Shauna Horvath, previously a brand strategy consultant to Amylyx, to Head of Global Marketing and Keith White to Head of Global Market Access.

Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercial Officer where he will lead global marketing, sales, market access, commercial operations, training, new product commercialization and commercial strategy for the Company.

Farmers in Uruguay will have a new solution to grow a more sustainable crop thanks to a new arrangement that will allow PGG Wrightson Seeds, New Zealand’s largest seed company, to distribute Marrone Bio Innovations, Inc.’s line of Pro Farm Technology products.

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced initial data from two clinical studies of galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP), maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment.